Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to Its Board of Directors
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to Its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Nov. 29, 2023-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced the appointment of John Quisel, J.D., Ph.D., President and CEO of Disc Medicine, to its Board of Directors.
聖地亞哥--(美國商業資訊)--2023年11月29日-- Gossamer Bio, Inc. 納斯達克股票代碼：GOSS）是一家臨床階段的生物製藥公司，專注於治療肺動脈高壓（PAH）的開發和商業化。該公司今天宣佈任命Disc Medicine總裁兼首席執行官約翰·奎塞爾爲董事會成員。
"Today, we are thrilled to announce that Dr. John Quisel has joined the Gossamer team," said Faheem Hasnain, Chairman, Co-Founder and CEO of Gossamer Bio. "Not only is Dr. Quisel a recognized industry leader with a proven track record of success, but he also brings unique strategic insights and experience in PAH, which will be invaluable. We are confident that Dr. Quisel's appointment enhances our ability to get seralutinib to patients."
Gossamer Bio董事長、聯合創始人兼首席執行官法希姆·哈斯南說：“今天，我們很高興地宣佈，約翰·奎塞爾博士已加入Gossamer團隊。“Quisel博士不僅是公認的行業領導者，擁有良好的成功記錄，而且他在PAH方面也帶來了獨特的戰略見解和經驗，這將是無價的。我們相信，Quisel醫生的任命增強了我們爲患者提供seralutinib的能力。”
"I am honored to join Gossamer's Board at this pivotal moment for the Company," said Dr. Quisel. "Despite recent advances, PAH remains a progressive and fatal disease, and for this reason I am excited to rejoin the fight against PAH with Gossamer."
奎塞爾博士說：“我很榮幸能在公司的關鍵時刻加入戈薩默董事會。”“儘管最近取得了進展，但多環芳烴仍然是一種進行性和致命的疾病，因此，我很高興能與Gossamer一起重新加入對抗多環芳烴的戰鬥。”
Dr. Quisel is currently the President and CEO of Disc Medicine, a position he has held since January 2020 and during which time, the company established a multi-product portfolio of hematology programs and became a publicly-traded company.
Quisel博士目前是Disc Medicine的總裁兼首席執行官，自2020年1月以來，他一直擔任該職務，在此期間，該公司建立了血液學項目的多產品組合，併成爲一家上市公司。
Previously, Dr. Quisel was the Executive Vice President and Chief Business Officer at Acceleron Pharma, where he spent more than thirteen years in various senior roles helping to build the company from a privately-held startup to a fully-integrated, publicly-traded company. Dr. Quisel led the initiative to re-acquire rights for sotatercept for pulmonary hypertension from Bristol-Myers Squibb, which eventually led to the acquisition of Acceleron by Merck & Co. for over $11 billion in 2021. During his tenure, Dr. Quisel also served in various roles, including Senior Vice President of Corporate Development and General Counsel. Prior to Acceleron, he was an attorney at the firms Ropes & Gray and Foley Hoag.
此前，Quisel博士曾在Acceleron Pharma擔任執行副總裁兼首席商務官，他在那裏擔任各種高級職務超過13年，幫助公司從一傢俬營初創公司發展成爲一家完全整合的上市公司。奎塞爾博士領導了從百時美施貴寶手中重新收購治療肺動脈高壓的索他西普版權的倡議，最終促使默沙東公司在2021年以超過110億美元的價格收購了Acceleron。在任職期間，Quisel博士還擔任過各種職務，包括企業發展高級副總裁和總法律顧問。在加入Acceleron之前，他曾在Ropes & Gray和Foley Hoag律師事務所擔任律師。
Dr. Quisel received an A.B. in biological sciences from Harvard College, an M.Sc. in biology from Stanford University, a Ph.D. in biology from the Massachusetts Institute of Technology, and a J.D. from Harvard Law School.
Quisel 博士擁有哈佛學院的生物科學學士學位、斯坦福大學的生物學碩士學位、麻省理工學院的生物學博士學位和哈佛法學院的法學博士學位。
About Gossamer Bio
關於 Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension.
Gossamer Bio是一家臨床階段的生物製藥公司，專注於治療肺動脈高壓的seralutinib的開發和商業化。其目標是成爲肺動脈高壓領域的行業領導者，改善肺動脈高壓患者的生活。
View source version on businesswire.com: https://www.businesswire.com/news/home/20231129247724/en/
For Investors and Media:
Bryan Giraudo, Chief Operating Officer and Chief Financial Officer
Gossamer Bio Investor Relations
ir@gossamerbio.com
對於投資者和媒體：
布萊恩·吉羅多，首席運營官兼首席財務官
Gossamer Bio 投資者關係
ir@gossamerbio.com
Source: Gossamer Bio, Inc.
來源：Gossamer Bio, Inc.
譯文內容由第三人軟體翻譯。